July 10, 2025
Headlines

Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib

Sumain Faisal01 mins

NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer’s biomarkers ahead of July 2025 presentation.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News